Tag Archives: imaging

Jan de Backer, CEO and founder of Fluidda, speaks about the partnership with Materialise at the ATS conference.

De Backer states: “We are very excited and proud to enter into this new phase of partnership with Materialise. We share the vision that the medical field, and particularly respiratory healthcare imaging needs to evolve towards personalized, precision medicine through a value-based healthcare approach. We are confident that advanced imaging techniques, such as our Functional Respiratory Imaging methods, can add value in this regard. “

CEO FLUIDDA appointed to Board of Directors of OSIC (Open Source Imaging Consortium)

Jan de Backer, CEO and founder of FLUIDDA, has been appointed to the Board of Directors of the new global non-profit organization OSIC (Open Source Imaging Consortium). The OSIC is a cooperative effort between academia, industry and philanthropy to enable rapid advances in the fight against Idiopathic Pulmonary Fibrosis (IPF) and other progressive interstitial lung… Continue Reading

CEO FLUIDDA now Member of advisory board Respiratory Innovation Summit (RIS)

Jan de Backer, MSc,PhD,MBA. CEO of FLUIDDA recently became member of the advisory board of the RIS. The Respiratory Innovation Summit unites the innovators, investors and clinicians who are leading the fight to create powerful new treatments for deadly and crippling diseases of the lungs and airways. Here you can find more information about the… Continue Reading

FLUIDDA moderates workshop on Functional Respiratory Imaging at the RDD 2019 congress, May 7-10, Estoril.

FLUIDDA moderates workshop on Functional Respiratory Imaging at the RDD 2019 congress, May 7-10, Estoril.

From May 7-10 the Respiratory Drug Delivery congress (RDD) will take place in Estoril, Portugal. This annual congress is focussed on the key-issues of developing inhaled therapies and novel inhalation devices for diseases of the upper- and lower airways. During this congress FLUIDDA N.V. organizes a workshop on Functional Respiratory Imaging (FRI), moderated by Cedric van… Continue Reading

How is FRI a solution to your research question?

How is FRI a solution to your research question?

  We’ve said it before: the respiratory field is the most expensive one in the pharmaceutical world. The low sensitivity of several clinical biomarkers make it difficult for therapy developers to limit the size of their trails. Similarly, in the clinical domain, high costs occur among others from insensitive or difficult measurements, late detection of… Continue Reading

Accurate Prediction of Lung Transplant Rejection by Combining Functional Respiratory Imaging (FRI) with Machine Learning

Chronic rejection or Bronchiolitis Obliterans Syndrome (BOS) remains the most important cause of death in lung transplant patients. Diagnosing BOS today is challenging due to the lack of sensitive lung function measurements. Spirometry only offers an overall assessment of the lung function without revealing any regional information. FLUIDDA’s FRI technology has proven to yield accurate… Continue Reading

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

All content © FLUIDDA 2019